BACKGROUND: Cognitive impairment is a common and debilitating symptom in patients with diffuse glioma, and is the result of multiple factors. We hypothesized that molecular tumor characteristics influence neurocognitive functioning (NCF), and aimed to identify tumor-related markers of NCF in diffuse glioma patients. METHODS: We examined the relation between cognitive performance (executive function, memory, and psychomotor speed) and intratumoral expression levels of molecular markers in treatment-naive patients with diffuse glioma. We performed a single-center study in a consecutive cohort, through a two-step design: (1) hypothesis-free differential expression and gene set enrichment analysis to identify candidate oncogenetic markers for cognitive impairment. Nineteen molecular markers of interest were derived from this set of genes, as well as from prior knowledge; (2) correlation of cognitive performance to intratumoral expression levels of these nineteen molecular markers, measured with immunohistochemistry. RESULTS: From 708 included patients with immunohistochemical data, we performed an in-depth analysis of neuropsychological data in 197, and differential expression analysis in 65 patients. After correcting for tumor volume and location, we found significant associations between expression levels of CD3 and IDH-1 and psychomotor speed; between IDH-1, ATRX, NLGN3, BDNF, CK2Beta, EAAT1, GAT-3, SRF, and memory performance; and between IDH-1, P-STAT5b, NLGN3, CK2Beta, and executive functioning. P-STAT5b, CD163, CD3, and Semaphorin-3A were independently associated after further correction for histopathological grade. CONCLUSION: Molecular characteristics of glioma can be independent determinants of patients' cognitive functioning. This suggests that besides tumor volume, location, and histological grade, variations in glioma biology influence cognitive performance through mechanisms that include perturbation of neuronal communication. These results pave the way towards targeted cognition improving therapies in neuro-oncology.
BACKGROUND: Cognitive impairment is a common and debilitating symptom in patients with diffuse glioma, and is the result of multiple factors. We hypothesized that molecular tumor characteristics influence neurocognitive functioning (NCF), and aimed to identify tumor-related markers of NCF in diffuse glioma patients. METHODS: We examined the relation between cognitive performance (executive function, memory, and psychomotor speed) and intratumoral expression levels of molecular markers in treatment-naive patients with diffuse glioma. We performed a single-center study in a consecutive cohort, through a two-step design: (1) hypothesis-free differential expression and gene set enrichment analysis to identify candidate oncogenetic markers for cognitive impairment. Nineteen molecular markers of interest were derived from this set of genes, as well as from prior knowledge; (2) correlation of cognitive performance to intratumoral expression levels of these nineteen molecular markers, measured with immunohistochemistry. RESULTS: From 708 included patients with immunohistochemical data, we performed an in-depth analysis of neuropsychological data in 197, and differential expression analysis in 65 patients. After correcting for tumor volume and location, we found significant associations between expression levels of CD3 and IDH-1 and psychomotor speed; between IDH-1, ATRX, NLGN3, BDNF, CK2Beta, EAAT1, GAT-3, SRF, and memory performance; and between IDH-1, P-STAT5b, NLGN3, CK2Beta, and executive functioning. P-STAT5b, CD163, CD3, and Semaphorin-3A were independently associated after further correction for histopathological grade. CONCLUSION: Molecular characteristics of glioma can be independent determinants of patients' cognitive functioning. This suggests that besides tumor volume, location, and histological grade, variations in glioma biology influence cognitive performance through mechanisms that include perturbation of neuronal communication. These results pave the way towards targeted cognition improving therapies in neuro-oncology.
Authors: Yanhong Liu; Renke Zhou; Erik P Sulman; Michael E Scheurer; Nicholas Boehling; Georgina N Armstrong; Spiridon Tsavachidis; Fu-Wen Liang; Carol J Etzel; Charles A Conrad; Mark R Gilbert; Terri S Armstrong; Melissa L Bondy; Jeffrey S Wefel Journal: Clin Cancer Res Date: 2015-04-22 Impact factor: 12.531
Authors: Andromachi Karakatsani; Nicolás Marichal; Severino Urban; Georgios Kalamakis; Alexander Ghanem; Anna Schick; Yina Zhang; Karl-Klaus Conzelmann; Markus A Rüegg; Benedikt Berninger; Carmen Ruiz de Almodovar; Sergio Gascón; Stephan Kröger Journal: Development Date: 2017-10-23 Impact factor: 6.868
Authors: Débora Junqueira; Ana M Brusque; Lisiane O Porciúncula; Liane N Rotta; Marcos E S Frizzo; Angela T S Wyse; Clóvis M D Wannmacher; Diogo O Souza; Moacir Wajner Journal: J Neurol Sci Date: 2004-02-15 Impact factor: 3.181
Authors: Varun Venkataramani; Dimitar Ivanov Tanev; Christopher Strahle; Alexander Studier-Fischer; Laura Fankhauser; Tobias Kessler; Christoph Körber; Markus Kardorff; Miriam Ratliff; Ruifan Xie; Heinz Horstmann; Mirko Messer; Sang Peter Paik; Johannes Knabbe; Felix Sahm; Felix T Kurz; Azer Aylin Acikgöz; Frank Herrmannsdörfer; Amit Agarwal; Dwight E Bergles; Anthony Chalmers; Hrvoje Miletic; Sevin Turcan; Christian Mawrin; Daniel Hänggi; Hai-Kun Liu; Wolfgang Wick; Frank Winkler; Thomas Kuner Journal: Nature Date: 2019-09-18 Impact factor: 49.962
Authors: Sharon Berendsen; Wim G M Spliet; Marjolein Geurts; Wim Van Hecke; Tatjana Seute; Tom J Snijders; Vincent Bours; Erica H Bell; Arnab Chakravarti; Pierre A Robe Journal: Cancers (Basel) Date: 2019-01-04 Impact factor: 6.639
Authors: Ingeborg Bosma; Jaap C Reijneveld; Martin Klein; Linda Douw; Bob W van Dijk; Jan J Heimans; Cornelis J Stam Journal: Nonlinear Biomed Phys Date: 2009-08-23